Investigational drug · Phase 2
JDQ443
Also called: Opnurasib
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "JDQ443"
First trial start
2021
Feb 24, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JDQ443", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
- Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
- Advanced Solid Tumors Harboring the KRAS G12C Mutation
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Colorectal
- Cancer of Lung
- Cancer of the Lung
- Lung Cancer
- Neoplasms, Lung
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JDQ443" as an intervention, largest first.
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04699188 · 344 participants · Start Feb 24, 2021 · Primary completion Jan 25, 2027
Drug: JDQ443; TNO155 and 1 more · For: KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal and 7 more
Sites: Atlanta, Georgia; Boston, Massachusetts; Pittsburgh, Pennsylvania · 38 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05445843 · 95 participants · Start Dec 6, 2022 · Primary completion Nov 4, 2024
Drug: JDQ443 · For: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Sites: Providence, Rhode Island; Pilar, Argentina; Córdoba, Argentina · 45 sites in all
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT05132075 · 95 participants · Start Jun 15, 2022 · Primary completion Sep 3, 2026
Drug: JDQ443; docetaxel · For: Non-Small Cell Lung Cancer
Sites: Renton, Washington; CABA, Argentina; Pilar, Argentina · 51 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05358249 · 74 participants · Start Oct 24, 2022 · Primary completion Sep 28, 2026
Drug: JDQ443; trametinib and 2 more · For: KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung and 8 more
Sites: Boston, Massachusetts; New York, New York; Leuven, Belgium · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05329623 · 33 participants · Start May 3, 2022 · Primary completion Apr 7, 2024
Drug: JDQ443 · For: Small Cell Lung Carcinoma
Sites: Orlando, Florida; San Antonio, Texas
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07468071 · 25 participants · Start Jun 8, 2026 · Primary completion Jun 11, 2029
Drug: Opnurasib; TNO155 and 3 more · For: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer; Advanced Solid Tumors Harboring the KRAS G12C Mutation
Sites: Sint-Niklaas, Belgium; Leuven, Belgium; Montreal, Canada · 21 sites in all
- Neoadjuvant Platform Trial in Non-Small Cell Lung CancerActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT05714891 · 4 participants · Start Sep 15, 2023 · Primary completion Dec 31, 2026
Drug: JDQ443 · For: NSCLC
Sites: Winnipeg, Canada; Kingston, Canada; London, Canada · 8 sites in all
Maastricht University Medical CenterAcademic, hospital or other
NCT05999357 · 0 participants · Start Apr 15, 2024 · Primary completion Aug 2027
Drug: JDQ443 · For: Non Small Cell Lung Cancer Metastatic; Brain Metastases, Adult; KRAS G12C
Newest research
PubMed records naming it or its code names, newest first.
- Dual-State KRAS G12C Inhibitors as Emerging Therapeutics for Brain and Lung Metastases.
Renner AC, Kargbo RB · ACS Med Chem Lett 2025
- Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC).
Herrmann A, Azenkot T, Hilburn V, et al. · Expert Opin Pharmacother 2025
- A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.
Spicer J, Blais N, Owen S, et al. · Clin Lung Cancer 2025
- ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.
Rijmers J, Retmana IA, Bui V, et al. · Biomed Pharmacother 2024
- Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study.
Retmana IA, Çelebi N, Rijmers J, et al. · J Chromatogr B Analyt Technol Biomed Life Sci 2024
- CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Prahallad A, Weiss A, Voshol H, et al. · Cancer Res 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.